A5221

A Strategy Study of Immediate Versus Deferred initiation of Antiretroviral Therapy for AIDS Disease-Free Survival in HIV-Infected Persons Treated for Tuberculosis with CD4

Sponsor: US National Institute of Allergy and Infectious Diseases (NIAID)

Protocol Summary: A5221 was a randomized, open-label study of HIV-1 infected participants treated for tuberculosis (TB). It was designed to determine whether the strategy of initiating ART immediately (within approximately two weeks after initiating TB treatment) reduces mortality and the incidence of other AIDS-defining events compared to later initiation of this population.

Years: 2007 – 2010

Investigator: James Hakim, MBChB, FRCP

Location: Parirenyatwa CRS

Comments are closed.

Website by Canton Becker